Format

Send to

Choose Destination
IDrugs. 2003 Feb;6(2):154-8.

Pralnacasan (vertex pharmaceuticals).

Author information

1
Universitatsklinikum Benjamin Franklin, Medizinische Klinik I, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. britta.siegmund@medizin.fu-berlin.de

Abstract

Vertex is collaborating with Aventis Pharma AG (formerly Hoechst Marion Roussel Inc) in the development of pralnacasan, an interleukin (IL)-1b converting enzyme (ICE) inhibitor, for the potential treatment of inflammatory diseases [170247], [188293], [453094].

PMID:
12789619
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center